Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.02.19.21252113: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Michael’s Hospital (Toronto, ON, Canada), as approved by the Research Ethics Board (REB# 20-078).
Consent: Informed consent was obtained from all patients or their legal surrogates.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Detailed methods are available (online supplement), including methods for detection of anti-nuclear autoantibodies (ANA) by HEp-2 immunofluorescence assay (IFA) (Inova Diagnostics, San Diego, CA USA), and antigen-specific autoantibodies (TheraDiag, Paris, France) and anti-cytokine autoantibodies (Millipore, Oakville, ON, … SciScore for 10.1101/2021.02.19.21252113: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Michael’s Hospital (Toronto, ON, Canada), as approved by the Research Ethics Board (REB# 20-078).
Consent: Informed consent was obtained from all patients or their legal surrogates.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources Detailed methods are available (online supplement), including methods for detection of anti-nuclear autoantibodies (ANA) by HEp-2 immunofluorescence assay (IFA) (Inova Diagnostics, San Diego, CA USA), and antigen-specific autoantibodies (TheraDiag, Paris, France) and anti-cytokine autoantibodies (Millipore, Oakville, ON, Canada) using addressable laser bead immunoassays. anti-nuclearsuggested: Noneantigen-specificsuggested: Noneanti-cytokinesuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The main limitation of our study is the small sample size. The strengths of our study include its prospective, contemporaneous COVID- cohort with similar severity of disease. Importantly, we tested a broad APLA serological panel longitudinally, providing a more robust assessment of its true prevalence and incidence than in other reported studies; this is particularly relevant for such acutely ill patients with dynamic clinical courses. Finally, our use of an extensive serological panel allowed us to better characterize the broad phenotype associated with aCL.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04747782 Recruiting COVID-19 Longitudinal Biomarkers in Lung Injury Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-